IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors

被引：0
作者：
Aggen, David H.
McKean, Meredith
Hoffman-Censits, Jean H.
Lakhani, Nehal J.
Alhalabi, Omar
Guancial, Elizabeth A.
Bashir, Babar
Bowman, I. Alex
Tan, Alan
Lingaraj, Trupti
Kim, Katherine
Timothy, Marissa
Ortiz-Otero, Nerymar
Bartolini, Wilmin
Kacena, Katherine
Santillana, Sergio
Luke, Jason J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Dept Urol, Baltimore, MD USA
[6] START Midwest, Grand Rapids, MI USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[8] Florida Canc Specialists & Res Inst, Sarasota, FL USA
[9] Thomas Jefferson Univ, Sarah Cannon Res Inst, Philadelphia, PA 19107 USA
[10] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[12] Rush Univ, Med Ctr, Chicago, IL USA
[13] Ikena Oncol, Boston, MA USA
[14] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2599
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE 1A/B STUDY OF IK-175, AN ORAL AHR INHIBITOR, ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH LOCALLY DVANCED OR METASTATIC SOLID TUMORS AND UROTHELIAL CARCINOMA
    McKean, Meredith
    Luke, Jason
    Lakhani, Nehal
    Bashir, Babar
    Aggen, David
    Tan, Alan
    Kacena, Katherine
    Wang, Lei
    Timothy, Marissa
    Santillana, Sergio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A425 - A425
  • [2] Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma
    McKean, Meredith
    Aggen, David Henry
    Lakhani, Nehal J.
    Bashir, Babar
    Luke, Jason J.
    Hoffman-Censits, Jean H.
    Alhalabi, Omar
    Bowman, Isaac Alex
    Guancial, Elizabeth A.
    Tan, Alan
    Lingaraj, Trupti
    Timothy, Marissa
    Kacena, Katherine
    Malek, Karim S.
    Santillana, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A PHASE 1B OPEN-LABEL, SINGLE-ARM DOSE EXPANSION STUDY OF IK-175, AN ORAL AHR INHIBITOR, IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH PRIMARY PD-1 INHIBITOR RESISTANT ADVANCED HEAD AND NECK CANCER
    Lingaraj, Trupti
    Timothy, Marissa
    Ortiz-Otero, Nerymar
    Bartolini, Wilmin
    Kacena, Katherine
    Malek, Karim
    Santillana, Sergio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A710 - A710
  • [4] INITIAL RESULTS FROM A PHASE 1A/B STUDY OF IK175, AN ORAL AHR INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS AND UROTHELIAL CARCINOMA
    Aggen, David
    McKean, Meredith
    Lakhani, Nehal
    Bashir, Babar
    Hoffman-Censits, Jean
    Alhalabi, Omar
    Guancial, Elizabeth
    Bowman, Isaac
    Tan, Alan
    Lingaraj, Trupti
    Timothy, Marissa
    Ortiz-Otero, Nerymar
    Bartolini, Wilmin
    Kacena, Katherine
    Malek, Karim
    Santillana, Sergio
    Luke, Jason
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A692 - A692
  • [5] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1073 - 1074
  • [6] Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)
    Falchook, Gerald Steven
    Ribas, Antoni
    Davar, Diwakar
    Eroglu, Zeynep
    Wang, Judy S.
    Luke, Jason J.
    Hamilton, Erika P.
    Di Pace, Brian
    Wang, Tianli
    Ghosh, Srimoyee
    Dhar, Arindam
    Borgovan, Theo
    Waszak, Angela
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
    Wei, Xiao X.
    Werner, Lillian
    Teo, Min Y.
    Rosenberg, Jonathan E.
    Koshkin, Vadim S.
    Grivas, Petros
    Szabados, Bernadett
    Morrison, Laura
    Powles, Thomas
    Carril-Ajuria, Lucia
    Castellano, Daniel
    Velho, Pedro Isaacsson
    Hahn, Noah M.
    McKay, Rana R.
    Raggi, Daniele
    Necchi, Andrea
    Kanesvaran, Ravindran
    Alerasool, Parissa
    Gaines, Jacob
    Galsky, Matthew
    Bellmunt, Joaquim
    Sonpavde, Guru
    JOURNAL OF UROLOGY, 2021, 205 (02) : 414 - 419
  • [8] Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors
    Hwang, Inhwan
    Park, Inkeun
    Yoon, Shin-kyo
    Lee, Jae Lyun
    CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E122 - E133
  • [9] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
  • [10] Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
    Tang, Quanqing
    Li, Shihao
    Huang, Gaozhen
    Liu, Hongwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 119
12345